논문검색
Author Joong Bae Ahn, Hee Chul Chung, Nae Choon Yoo, Jae Kyung Roh, Nam Kyu Kim, Chang Ok Suh4, Gwi Eon Kim4, Jin Sil Seong4, Woong Ho Shim6, Hyun Cheol Chung
Place of duty 1Center for Colorectal Cancer, National Cancer Center, Departments of 2Internal Medicine, 3General Surgery and 4Radiation Oncology, Yonsei University College of Medicine, 5Yonsei Cancer Center, 6Brain Korea 21 Project for Medical Science.
Title Efficacy of Postoperative Concurrent Chemoradiation for Resectable Rectal Cancer: A Single Institute Experience
Publicationinfo Cancer Research and Treatment 2004 Aug; 036(04): 228-234.
Key_word 5-fluorouracil,Dose intensity,Adjuvant chemotherapy,Rectal cancer
Full-Text
Abstract Purpose: For patients with Dukes' stage B and C rectal cancer, surgery followed by adjuvant chemoradiotherapy is considered to be the standard treatment. However, the drugs used in combination with 5-fluorouracil (5-FU), the method of administration, duration of adjuvant therapy and the frequencies of administration presently remain controversial topics. We investigated (1) the efficacy and safety of adjuvant radiotherapy and 5-FU/leucovorin (LV) chemotherapy for patients who had undergone curative resection and (2) the effect of dose related factors of 5-FU on survival. Materials and Methods: 130 rectal cancer patients with Dukes' B or C stage disease who were treated with curative resection were evaluated. The adjuvant therapy consisted of two cycles of 5-FU/LV chemotherapy followed by pelvic radiotherapy with chemotherapy, and then 4~10 more cycles of the same chemotherapy regimen were delivered based on the disease stage. The cumulative dose of 5-FU per body square meter (BSA), actual dose intensity and relative dose intensity were obtained. The patients were divided into two groups according to the median value of each factor, and the patients' survival rates were compared. Results: With a median follow-up duration of 52 months, the 5-year disease-free survival and overall survival rates of 130 patients were 57& and 73&, respectively. Loco- regional failure occurred in 17 (13&) of the 130 patients, and the distant failure rate was 27& (35/130). The chemotherapy related morbidity was minimal, and there was no mortality for these patients. The cumulative dose of 5-FU/ BSA had a significant effect on the 5-year overall survival for Dukes' C rectal cancer patients (p=0.03). Multivariate analysis demonstrated that only the performance status affected the 5-year overall survival (p=0.003). Conclusion: An adjuvant therapy of radiotherapy and 5-FU/LV chemotherapy is effective and tolerable for Dukes' B and C rectal cancer patients. A prospective, multicenter, randomized study to evaluate the effects of the cumulative dose of 5-FU/BSA on survival is required. (Cancer Research and Treatment 2004;36:228-234)